σ(α) trait stability across diverse cognitive and pharmacological contexts: a single-operator longitudinal observation from consumer EEG
Zenodo (CERN European Organization for Nuclear Research) May 14, 2026 DOI: 10.5281/zenodo.20187833 via OpenAlex
Summary
In a 19-day single-operator longitudinal observation, a candidate EEG trait signature called σ(α) — the rolling standard deviation of channel-averaged smoothed alpha — remained within a narrow 0.125–0.184 band across 21 sessions covering deep rest, exercise, gaming, cannabinoid and prescription stimulant states. The stimulant session produced an attenuated EEG signature (α/β = 1.38, σ(α) = 0.132) consistent with the operator's poor-metabolizer pharmacogenetic profile. Applying Stanford ibogaine-pipeline metrics showed partial convergence at calm-rest baseline but divergence in resting theta/beta ratio. σ(α) was statistically independent of peak alpha frequency and Lempel-Ziv complexity, suggesting it indexes a distinct facet of cortical organization. These n=1 observations on consumer hardware are consistent with, but do not prove, a regulation-stability trait signature.
Study at a glance
| Characteristics | Longitudinal observation report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | Single operator (the author) |
| Keywords | Electroencephalography Stimulant Trait Cognition Neuroimaging |
| Key finding | The candidate trait signature σ(α) held within a narrow 0.125–0.184 band across all 21 sessions and was statistically independent of peak alpha frequency and Lempel-Ziv complexity, suggesting it indexes a distinct facet of cortical organization. |
Abstract
This is a preliminary, single-operator longitudinal observation report. Over a 19-day recording window spanning April 20 to May 8, 2026, one operator (the author) recorded 21 valid 250 Hz Muse Athena consumer EEG sessions across deep rest, sustained dialogue + running, multiplayer gaming, cannabinoid pharmacological states at four dose-duration profiles, prescription stimulant administration during a documented dose titration in a CYP2D6 5/41 poor metabolizer, a 5-hour sustained articulation session, and a documented startle event during outdoor running. A candidate trait signature — σ(α), defined as the 60-second rolling standard deviation of channel-averaged smoothed alpha — held within a narrow 0.125–0.184 band across all 21 sessions. The single eyes-closed calm-rest session in the cohort produced σ(α) = 0.155. The prescription stimulant session produced an attenuated rather than strongly activating EEG signature (α/β = 1.38, σ(α) = 0.132, mean HR = 93 bpm), consistent with the operator’s documented poor-metabolizer pharmacogenetic profile. Applying the Stanford Brain Stimulation Lab’s ibogaine-pipeline metrics (Lissemore et al., 2025) to the same dataset shows partial convergence at the calm-rest baseline — peak alpha frequency 8.75 Hz (low end of the normal adult range), Lempel-Ziv complexity 0.645 (mid-range), and a strong negative LZc ↔ theta/beta correlation across sessions (r = −0.66, p = 0.001) that matches the direction Stanford reports for treatment response — alongside a clear divergence in resting theta/beta ratio (0.65, opposite the post-treatment direction). σ(α) is statistically independent of PAF (p = 0.32) and LZc (p = 0.23) across sessions, indicating it indexes a distinct facet of cortical organization. These are n = 1 observations on consumer hardware; they are consistent with — but do not prove — the existence of a regulation-stability trait signature distinct from existing power- and complexity-based EEG metrics. Multi-operator replication is invited.